Melatonin not found to improve fatigue in patients with advanced cancer
the ONA take:
According to a new study published online ahead of print in the journal Cancer, researchers at Bispebjerg Hospital in Copenhagen, Denmark, have found use of oral melatonin at a dose of 20 mg was not associated with improvement in fatigue or other symptoms in patients with advanced cancer.
For the study, researchers sought to assess the effect of melatonin on fatigue and other symptoms in patients with advanced cancer. Researchers enrolled 72 patients with stage IV cancer who reported significant fatigue and randomly assigned them to receive 1 week of melatonin 20 mg or placebo orally each night. Patients then crossed over and received the opposite treatment for 1 week.
Of those, 50 patients completed the study and 44 were 100% compliant with the interventions. Results showed no difference in physical fatigue or other quality of life measures between melatonin and placebo.
Oral melatonin was not associated with improvement in fatigue or other symptoms in patients with advanced cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|